Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time.


Journal

BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721

Informations de publication

Date de publication:
09 2023
Historique:
medline: 16 8 2023
pubmed: 19 3 2023
entrez: 18 3 2023
Statut: ppublish

Résumé

To test the hypothesis that longer warm ischaemia time (WIT) might have a marginal impact on renal functional outcomes and might, in fact, reduce haemorrhagic risk intra-operatively. Data from 1140 patients treated with elective partial nephrectomy (PN) for a cT1-2 cN0 cM0 renal mass were prospectively collected. WIT was defined as the duration of clamping of the main renal artery with no refrigeration and was tested as a continuous variable. The primary outcome of the study was evaluation of the effect of WIT on renal function (estimated glomerular filtration rate [eGFR]) postoperatively, at 6 months and in the long term (measured between 1 and 5 years after surgery). The secondary outcome of the study was haemorrhagic risk, defined as estimated blood loss (EBL) or peri-operative transfusions. Multivariable linear, logistic and Cox regression analyses, accounting for age, Charlson comorbidity index, clinical size, preoperative eGFR and year of surgery, were used and the potential nonlinear relationship between WIT and the study outcomes was modelled using restricted cubic splines. A total of 863 patients (76%) underwent PN with WIT and 277 (24%) without. The baseline median eGFR was 87.3 (68.8-99.2) mL/min/1.73m Patients and clinicians should be aware that performing PN with very limited or even with zero WIT might increase bleeding and the need for peri-operative transfusion while not improving long-term renal function outcomes.

Identifiants

pubmed: 36932928
doi: 10.1111/bju.16009
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

283-290

Informations de copyright

© 2023 BJU International.

Références

Van Poppel H, Da Pozzo L, Albrecht W et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011; 59: 543-52
Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 2014; 65: 372-7
Ljungberg B, Albiges L, Bedke J et al. EAU guidelines on renal cell carcinoma presented at the EAU annual congress Amsterdam 2022. Eur Urol 2022; 82: 399
Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I. J Urol 2021; 206: 199-208
Cignoli D, Fallara G, Larcher A, Rosiello G, Montorsi F, Capitanio U. How to improve outcome in nephron-sparing surgery: the impact of new techniques. Curr Opin Urol 2021; 31: 255-61
Campbell SC, Campbell JA, Munoz-Lopez C, Rathi N, Yasuda Y, Attawettayanon W. Every decade counts: a narrative review of functional recovery after partial nephrectomy. BJU Int 2022; 131: 165-72
Klatte T, Ficarra V, Gratzke C et al. A literature review of renal surgical anatomy and surgical strategies for partial nephrectomy. Eur Urol 2015; 68: 980-92
Paulucci DJ, Rosen DC, Sfakianos JP et al. Selective arterial clamping does not improve outcomes in robot-assisted partial nephrectomy: a propensity-score analysis of patients without impaired renal function. BJU Int 2017; 119: 430-5
Stonier T, Rai BP, Trimboli M et al. Early vs. standard unclamping technique in minimal access partial nephrectomy: a meta-analysis of observational cohort studies and the lister cohort. J Robot Surg 2017; 11: 389-98
Thompson RH, Lane BR, Lohse CM et al. Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol 2010; 58: 340-5
Greco F, Autorino R, Altieri V et al. Ischemia techniques in nephron-sparing surgery: a systematic review and meta-analysis of surgical, oncological, and functional outcomes. Eur Urol 2019; 75: 477-91
Ginsburg KB, Schober JP, Kutikov A. Ischemia time has little influence on renal function following partial nephrectomy: is it time for urology to stop the tick-tock dance? Eur Urol 2022; 81: 501-2
Capitanio U, Larcher A, Fallara G et al. Parenchymal biopsy in the management of patients with renal cancer. World J Urol 2021; 39: 2961-8
Ginzburg S, Uzzo R, Walton J et al. Residual parenchymal volume, not warm ischemia time, predicts ultimate renal functional outcomes in patients undergoing partial nephrectomy. Urology 2015; 86: 300-5
Cacciamani GE, Medina LG, Gill TS et al. Impact of renal hilar control on outcomes of robotic partial nephrectomy: systematic review and cumulative meta-analysis. Eur Urol Focus 2019; 5: 619-35
Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12
Ficarra V, Crestani A, Bertolo R et al. Tumour contact surface area as a predictor of postoperative complications and renal function in patients undergoing partial nephrectomy for renal tumours. BJU Int 2019; 123: 639-45
Ficarra V, Novara G, Secco S et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol 2009; 56: 786-93
Vickers AJ, Sjoberg DD. Guidelines for reporting of statistics in European urology. Eur Urol 2015; 67: 181-7
Antonelli A, Cindolo L, Sandri M et al. Is off-clamp robot-assisted partial nephrectomy beneficial for renal function? Data from the CLOCK trial. BJU Int 2022; 129: 217-24
Xiong L, Nguyen JK, Peng Y et al. What happens to the preserved renal parenchyma after clamped partial nephrectomy? Eur Urol 2022; 81: 492-500
Parekh DJ, Weinberg JM, Ercole B et al. Tolerance of the human kidney to isolated controlled ischemia. J Am Soc Nephrol 2013; 24: 506-17
Mir MC, Ercole C, Takagi T et al. Decline in renal function after partial nephrectomy: etiology and prevention. J Urol 2015; 193: 1889-98
Porpiglia F, Fiori C, Bertolo R et al. Long-term functional evaluation of the treated kidney in a prospective series of patients who underwent laparoscopic partial nephrectomy for small renal tumors. Eur Urol 2012; 62: 130-5
Bravi CA, Mari A, Larcher A et al. Toward individualized approaches to partial nephrectomy: assessing the correlation between ischemia time and patient health status (RECORD2 project). Eur Urol Oncol 2021; 4: 645-50
McIntosh AG, Parker DC, Egleston BL et al. Prediction of significant estimated glomerular filtration rate decline after renal unit removal to aid in the clinical choice between radical and partial nephrectomy in patients with a renal mass and normal renal function. BJU Int 2019; 124: 999-1005
Rosiello G, Larcher A, Fallara G et al. A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy - A large, retrospective, single-center study. Urol Oncol 2022; 41: 149.e17-25
Antonelli A, Cindolo L, Sandri M et al. Safety of on- vs off-clamp robotic partial nephrectomy: per-protocol analysis from the data of the CLOCK randomized trial. World J Urol 2020; 38: 1101-8
Simone G, Gill IS, Mottrie A et al. Indications, techniques, outcomes, and limitations for minimally ischemic and off-clamp partial nephrectomy: a systematic review of the literature. Eur Urol 2015; 68: 632-40
Rosiello G, Larcher A, Fallara G et al. The impact of intraoperative bleeding on the risk of chronic kidney disease after nephron-sparing surgery. World J Urol 2020; 39: 2553-8

Auteurs

Daniele Cignoli (D)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Giuseppe Basile (G)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Giuseppe Fallara (G)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Giuseppe Rosiello (G)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Federico Belladelli (F)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Francesco Cei (F)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Giacomo Musso (G)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Chiara Re (C)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Roberto Bertini (R)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Pierre Karakiewicz (P)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada.

Alexandre Mottrie (A)

Department of Urology, OLV Ziekenhuis Aalst, Aalst, Belgium.
ORSI Academy, Melle, Belgium.

Federico Dehò (F)

Department of Urology, Ospedale di Circolo e Fondazione Macchi-ASST Sette Laghi, University of Insubria, Varese, Italy.

Andrea Gallina (A)

Department of Urology, Ospedale Regionale di Lugano, Civico USI-Università della Svizzera Italiana, Lugano, Switzerland.

Francesco Montorsi (F)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Andrea Salonia (A)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Umberto Capitanio (U)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Alessandro Larcher (A)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH